Aerospace alloys are doing the heavy lifting
- Carpenter's core SAO segment hit a record 35.6% adjusted operating margin in Q3 FY2026.
- Aerospace and Defense is the main demand engine, with Q3 sales up 17% from the prior year.
- Medical is the sore spot, with Q3 sales excluding surcharges down 29% from the prior year.
- Management said fiscal 2027 earnings guidance is outdated and will be raised on the next call.
- The stock has a stronger performance story than valuation story, so future guidance needs to matter.
A great core, one weak limb
Carpenter's story is now simple. Its main Specialty Alloys Operations business, or SAO, is running very well. In Q3 FY2026, SAO reached a record 35.6% adjusted operating margin, up from 33.1% in the prior quarter and 29.1% a year earlier.
The bull case rests on aerospace. Customers are ordering more material for aircraft and defense uses, and management says some customers want longer long term agreements. That matters because longer deals can mean better visibility and more pricing power when supply is tight.
The bear case has not gone away. Medical sales fell 23% in Q3 FY2026, and fell 29% excluding surcharge revenue. Management said bookings were up significantly, which may signal a turn, but the recovery has not yet shown up in reported sales.
Expectations are also higher now. Management said its fiscal 2027 earnings target is outdated and will give an updated view on the next earnings call. That is good for momentum, but it also raises the bar for the stock.
Special metals for hard jobs
Carpenter makes premium alloys, including titanium alloys, powder metals, stainless steels, alloy steels, and tool steels. These materials go into places where failure is costly, such as aircraft engines, defense systems, implants, turbines, and other demanding equipment.
The company makes money by turning raw materials like nickel, cobalt, titanium, chromium, and iron scrap into billet, bar, rod, wire, strip, powders, and parts. It sells through plants, service centers, distributors, and direct customer relationships.
A key part of the model is pricing. Raw material surcharges help pass through metal cost changes, while long term agreements can lock in customer demand. In Q3 FY2026, the company said 43% of net sales for the first nine months were under firm price sales arrangements.
The model can break if aircraft demand slows, if medical destocking lasts longer, if raw material hedges and customer schedules do not line up, or if the company cannot run its specialized melt and finishing assets well.
Where the alloys go
Aerospace and defense alloys
This is the biggest demand driver. Q3 FY2026 sales to Aerospace and Defense were $534.2 million, up 17% from the prior year.
Medical titanium and specialty materials
Medical should be a strong end market over time, but it is weak right now. Q3 FY2026 Medical sales were $65.8 million, down 23% from the prior year.
Energy materials
Energy is getting help from power generation demand, including materials for industrial gas turbines. Q3 FY2026 Energy sales rose 49% from the prior year.
Industrial and consumer materials
This bucket includes markets such as semiconductor materials, fluid control, and consumer electronics. Q3 FY2026 Industrial and Consumer sales rose 7% from the prior year.
Powders and additive products
Carpenter also produces metal powders and parts. This sits inside the smaller PEP segment, where improving Additive profitability helped offset some Medical weakness in Q3 FY2026.
Distribution and service centers
The company runs service and distribution centers in the United States, Canada, Mexico, Europe, and Asia. These help customers with stocking programs and smaller, faster orders.
SAO carries the company
The mix uses Q3 FY2026 segment sales before intersegment eliminations: SAO at $735.1 million and PEP at $97.7 million. SAO is much larger and far more profitable, so the company is exposed to the aerospace cycle.
What could trip it up
Medical recovery does not arrive
Medium impact · Medium oddsMedical sales are still falling, even though management said bookings improved. If hospitals, device makers, or distributors keep cutting inventory, the PEP segment may stay weak longer than bulls expect.
Aerospace cycle cools
High impact · Medium oddsAerospace and Defense is now the main engine. A production delay at aircraft makers, weaker defense budgets, or lower customer orders could hurt volume, mix, and pricing.
Margins stop expanding
High impact · Medium oddsSAO has posted seventeen straight quarters of higher adjusted operating margins. That is excellent, but it also makes future comparisons harder. If mix worsens or productivity gains slow, investors may question peak earnings.
Capital spending and expansion risk
Medium impact · Medium oddsCarpenter is investing in a brownfield expansion to add melt capacity. The company now expects fiscal 2026 capital expenditures of about $260.0 million. Cost overruns, delays, or weak demand when capacity arrives would reduce the payoff.
Leadership handoff
Medium impact · Low oddsA CEO transition is effective July 1, 2026. The risk is not that a new leader is bad by default. The risk is that execution slips during a period when pricing, capacity, and customer agreements all matter.
In one breath
What does Carpenter Technology actually make?
Carpenter makes premium specialty alloys and engineered metal products. These include titanium alloys, powder metals, stainless steels, alloy steels, and tool steels used in aerospace, defense, medical, energy, and industrial markets.
Why is Aerospace and Defense so important to CRS?
It is the largest end market and the main source of growth right now. In Q3 FY2026, Aerospace and Defense sales were $534.2 million, up 17% from the prior year.
What is the main risk for Carpenter stock?
The biggest company specific risk is that Medical remains weak while investors are paying for strong aerospace growth. The bigger market risk is a slowdown in aircraft and defense demand.
What should investors watch next?
The next major item is management's updated fiscal 2027 guidance. Investors should also watch SAO margins, Medical sales growth, and any detail on pricing and length of new long term agreements.